

Topical steroids can change course of vulvar lichen sclerosus

15 June 2015



"Individualized preventive TCS regimens that achieve objective normality of skin color and texture and are used by compliant patients who attend regular long-term follow-up visits may modify the course of the disease," the authors write.

More information: Abstract

Full Text

Editorial (subscription or payment may be required)

More Information

Copyright © 2015 HealthDay. All rights reserved.

(HealthDay)—For adult patients with vulvar lichen sclerosus (VLS), long-term preventive topical corticosteroid (TCS) treatment is associated with improved outcomes, according to a study published online June 12 in *JAMA Dermatology*. The research was published to coincide with the World Congress of Dermatology, held from June 8 to 13 in Vancouver, Canada.

Andrew Lee, M.B.B.S., from Sydney Medical School Northern at the University of Sydney, and colleagues examined the impact of long-term preventive TCS treatment of various potencies, adjusted to meet a target outcome of normal skin color and texture. Data were collected from a prospective longitudinal cohort study involving 507 women with biopsy-proved VLS.

The researchers found that potent TCS, followed by regular preventive TCS treatment, induced remission. Overall, 29.6 and 70.4 percent of patents were considered partially compliant and fully compliant with treatment. During follow-up, 0 and 4.7 percent of the fully compliant and partially compliant patients had biopsy-proven squamous cell carcinoma or vulvar intraepithelial neoplasia (P

1/2



APA citation: Topical steroids can change course of vulvar lichen sclerosus (2015, June 15) retrieved 27 August 2022 from https://medicalxpress.com/news/2015-06-topical-steroids-vulvar-lichen-sclerosus.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.